Key result
Yiqi Fumai Formula improves cardiac function and inhibits cardiomyocyte ferroptosis in acute decompensated heart failure.
Why the study?
The mechanism by which Yiqi Fumai Formula exerts cardioprotective effects in acute decompensated heart failure via the Nrf2/SLC7A11/GPX4 pathway regulating ferroptosis was unclear.
Does Yiqi Fumai Formula improve cardiac function and inhibit ferroptosis in rat models of acute decompensated heart failure?
Does Yiqi Fumai Formula improve cardiac function and inhibit ferroptosis in rat models of acute decompensated heart failure?
Yiqi Fumai Formula exerts cardioprotective effects in a rat model of acute decompensated heart failure by suppressing ferroptosis via the Nrf2-SLC7A11/GPX4 pathway.
Hypothesis-generating for YQFM in ADHF ferroptosis; leaves open clinical efficacy and safety in patients.
OBJECTIVE: To elucidate the mechanism of Yiqi Fumai Formula (YQFM) in acute decompensated heart failure (ADHF) via the Nrf2/SLC7A11/GPX4 pathway in regulating ferroptosis. METHODS: Network pharmacology was employed to predict the underlying mechanisms of YQFM in ADHF. Rat models of ADHF were established, incorporating agonists or inhibitors of key ferroptosis pathways. The therapeutic mechanism of Yiqifumai Formula was investigated by assessing cardiac structure/function, myocardial injury biomarkers, lipid peroxidation, iron metabolism, ultrastructural changes, and key ferroptosis pathways. RESULTS: Network pharmacology analysis suggested that YQFM might intervene in ADHF by modulating key processes of ferroptosis, including lipid metabolism, inflammatory response, and cell survival. Experimental validation confirmed that YQFM improved cardiac function, reduced myocardial lipid peroxidation, and inhibited cardiomyocyte ferroptosis in rat models. This cardioprotective effect is likely associated with the regulation of the Nrf2/SLC7A11/GPX4 signaling pathway. CONCLUSION: YQFM exerts the cardioprotective effect in ADHF by suppressing ferroptosis through the modulation of the Nrf2-SLC7A11/GPX4 pathway.
No takes yet. Share an insight, caveat, or question.
Fan et al. (2026) studied Acute decompensated heart failure (ADHF). Yiqi Fumai Formula (YQFM) was evaluated on Cardiac function, myocardial lipid peroxidation, and cardiomyocyte ferroptosis. Yiqi Fumai Formula improved cardiac function and inhibited cardiomyocyte ferroptosis in acute decompensated heart failure rat models via the Nrf2-SLC7A11/GPX4 pathway.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: